Wilmington-based Noramco – a global active pharmaceutical ingredients (API) manufacturer specializing in controlled substances – completed the acquisition of the Cambrex Drug Product Business Unit, previously known as Halo Pharmaceuticals.
This acquisition will provide customers of Noramco and its subsidiary Purisys with additional service options such as drug product formulation development, clinical and commercial drug product manufacturing, and packaging from facilities in Mirabel, Québec and Whippany, NJ. Noramco is returning the business to the Halo Pharmaceutical brand.
“This acquisition allows Noramco to provide our customers with more sourcing options beyond APIs. With these additional capabilities, Noramco/Purisys customers can develop drug product formulations for their APIs for both clinical and commercial purposes,” said Noramco CEO Lee Karras. “Having previously operated the Halo Pharmaceuticals business, I have a direct appreciation of the capabilities of both sites and look forward to working with existing and future customers while welcoming the almost 400 new employees to the Noramco group of companies.”
Noramco has sites in Wilmington and Athens, GA. It is one of the companies owned by SK Capital, a private equity firm.
